Skip to main content

Selected Publications

  1. Youngblood MW, Erson-Omay Z, Li C, Najem H, Coșkun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S et al. Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas. Nat Commun 2023 Oct 07;14(1):6279. pii:6279
  2. Lukas RV, Horbinski C Glioma Response to IDH Inhibition: Real-World Experience. Clin Cancer Res 2023 Sep 22;. doi:10.1158/1078-0432.CCR-23-2164
  3. Johnson M, Bell A, Lauing KL, Ladomersky E, Zhai L, Penco-Campillo M, Shah Y, Mauer E, Xiu J, Nicolaides T et al. Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence. Clin Cancer Res 2023 Sep 19;. doi:10.1158/1078-0432.CCR-23-0834
  4. Nabors B, Portnow J, Hattangadi-Gluth J, Horbinski C NCCN CNS Tumor Guidelines Update for 2023. Neuro Oncol 2023 Sep 14;. pii:noad169
  5. Pang L, Dunterman M, Guo S, Khan F, Liu Y, Taefi E, Bahrami A, Geula C, Hsu WH, Horbinski C et al. Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma. Nat Immunol 2023 Oct;24(10):1654-1670. doi:10.1038/s41590-023-01605-y
  6. Zeng C, Song X, Zhang Z, Cai Q, Cai J, Horbinski C, Hu B, Cheng SY, Zhang W Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis. Acta Neuropathol Commun 2023 Aug 14;11(1):133. pii:133
  7. Stamm B, DiBiase R, Lee J, Primdahl D, Malavia T, Dixit K, Horbinski C, Kostelecky N, Elhodaky M, Potts MB et al. A Woman With Multifocal Ischemic Strokes and Progressive Cognitive Impairment due to Intravascular Lymphoma. Stroke 2023 Oct;54(10):e448-e451. doi:10.1161/STROKEAHA.123.043934
  8. Meredith DM, Cooley LD, Dubuc A, Morrissette J, Sussman RT, Nasrallah MP, Rathbun P, Yap KL, Wadhwani N, Bao L et al. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients. Mod Pathol 2023 Jul 31;36(11):100294. doi:10.1016/j.modpat.2023.100294
  9. Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, Lenzen AC, Heimberger AB, DeCuypere M Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review. Cancers (Basel) 2023 Jul 18;15(14). pii:3655
  10. Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A et al. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing. Neurooncol Adv 2023;5(1):vdad076. pii:vdad076
  11. Murnan KM, Horbinski C, Stegh AH Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma. Antioxid Redox Signal 2023 Jun 20;. doi:10.1089/ars.2023.0262
  12. Drumm MR, Wang W, Sears TK, Bell-Burdett K, Javier R, Cotton KY, Webb B, Byrne K, Unruh D, Thirunavu V et al. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. J Clin Invest 2023 Jun 15;133(12). pii:e168035
  13. Jo J, Diaz M, Horbinski C, Mackman N, Bagley S, Broekman M, Rak J, Perry J, Pabinger I, Key NS et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro Oncol 2023 Aug 03;25(8):1381-1394. doi:10.1093/neuonc/noad059
  14. Goenka A, Song X, Tiek D, Iglesia RP, Lu M, Zeng C, Horbinski C, Zhang W, Hu B, Cheng SY Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis. Neuro Oncol 2023 Sep 05;25(9):1592-1604. doi:10.1093/neuonc/noad065
  15. Ghorbani A, Avery LM, Sohaei D, Soosaipillai A, Richer M, Horbinski C, McCortney K, Xu W, Diamandis EP, Prassas I Discovery of novel glioma serum biomarkers by proximity extension assay. Clin Proteomics 2023 Mar 24;20(1):12. pii:12
  16. Jamshidi P, McCord M, Galbraith K, Santana-Santos L, Jennings LJ, Snuderl M, Horbinski C Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors. Acta Neuropathol 2023 Mar;145(3):365-367. doi:10.1007/s00401-023-02542-8
  17. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw 2023 Jan;21(1):12-20. doi:10.6004/jnccn.2023.0002
  18. McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN et al. Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. Cancers (Basel) 2022 Nov 09;14(22). pii:5494
  19. Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC et al. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem 2022 Dec 08;65(23):15642-15662. doi:10.1021/acs.jmedchem.2c00771
  20. Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023 Mar 16;141(11):1322-1336. doi:10.1182/blood.2022017858
  21. Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP et al. Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 2023 Jan;145(1):71-82. doi:10.1007/s00401-022-02513-5
  22. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 2023 Jan 05;25(1):4-25. doi:10.1093/neuonc/noac207
  23. Zhang Y, Nguyen CC, Zhang NT, Fink NS, John JD, Venkatesh OG, Roe JD, Hoffman SC, Lesniak MS, Wolinsky JP et al. Neurological applications of belzutifan in von Hippel-Lindau disease. Neuro Oncol 2023 May 04;25(5):827-838. doi:10.1093/neuonc/noac234
  24. Lauko A, Volovetz J, Turaga SM, Bayik D, Silver DJ, Mitchell K, Mulkearns-Hubert EE, Watson DC, Desai K, Midha M et al. SerpinB3 drives cancer stem cell survival in glioblastoma. Cell Rep 2022 Sep 13;40(11):111348. doi:10.1016/j.celrep.2022.111348
  25. Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S et al. Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas. Neuro Oncol 2023 Mar 14;25(3):508-519. doi:10.1093/neuonc/noac206
  26. Horbinski C, Berger T, Packer RJ, Wen PY Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol 2022 Sep;18(9):515-529. doi:10.1038/s41582-022-00679-w
  27. Santana-Santos L, Kam KL, Dittmann D, De Vito S, McCord M, Jamshidi P, Fowler H, Wang X, Aalsburg AM, Brat DJ et al. Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors. J Mol Diagn 2022 Aug;24(8):924-934. doi:10.1016/j.jmoldx.2022.04.009
  28. Smith HL, Wadhwani N, Horbinski C Major Features of the 2021 WHO Classification of CNS Tumors. Neurotherapeutics 2022 Oct;19(6):1691-1704. doi:10.1007/s13311-022-01249-0
  29. Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J et al. Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. Clin Cancer Res 2022 Jul 15;28(14):3156-3169. doi:10.1158/1078-0432.CCR-21-2563
  30. Cheng C, Geng F, Li Z, Zhong Y, Wang H, Cheng X, Zhao Y, Mo X, Horbinski C, Duan W et al. Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth. Nat Metab 2022 May;4(5):575-588. doi:10.1038/s42255-022-00568-y
  31. Rammohan N, Ho A, Saxena M, Bajaj A, Kruser TJ, Horbinski C, Korutz A, Tate M, Sachdev S Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma. J Neurooncol 2022 Jul;158(3):331-339. doi:10.1007/s11060-022-04018-3
  32. Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A et al. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight 2022 May 09;7(9). pii:e157612
  33. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C et al. Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2022 Mar;3(3):373. doi:10.1038/s43018-022-00343-8
  34. Javier R, Wang W, Drumm M, McCortney K, Sarkaria JN, Horbinski C The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma. PLoS One 2022;17(2):e0257725. pii:e0257725
  35. Drumm M, Templer JW, Tate M, Jennings L, Horbinski C Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation. Neurooncol Adv 2022;4(1):vdac004. pii:vdac004
  36. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C et al. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2021 Dec;2(12):1372-1386. doi:10.1038/s43018-021-00260-2
  37. Xu D, Bhattacharyya S, Wang W, Ifergan I, Wong MAC, Procissi D, Yeldandi A, Bale S, Marangoni RG, Horbinski C et al. PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis. JCI Insight 2022 Mar 08;7(5). pii:e151037
  38. Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathol 2022 Mar;143(3):403-414. doi:10.1007/s00401-022-02404-9
  39. Bitar M, Chornenkyy Y, Flanagan ME, Steffens A, McCortney K, Horbinski C The Frequency of Focal Cortical Dysplasia-Like Histologic Features Near Adult-Type Diffuse Gliomas. J Neuropathol Exp Neurol 2022 Jan 21;81(1):48-53. doi:10.1093/jnen/nlab120
  40. Larkin CJ, Jennings LJ, Heimberger AB, Horbinski C Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation. J Neuropathol Exp Neurol 2022 Feb 24;81(3):239-241. doi:10.1093/jnen/nlab114
  41. Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P et al. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol 2021;12:745893. pii:745893
  42. Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L et al. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv 2021;3(1):vdab125. pii:vdab125
  43. Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X et al. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res 2021 Dec 01;27(23):6514-6528. doi:10.1158/1078-0432.CCR-21-1392
  44. Boudreau CE, Najem H, Ott M, Horbinski C, Fang D, DeRay CM, Levine JM, Curran MA, Heimberger AB Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clin Cancer Res 2021 Oct 15;27(20):5528-5535. doi:10.1158/1078-0432.CCR-21-1914
  45. Gonzalez-Buendia E, Zhao J, Wang L, Mukherjee S, Zhang D, Arrieta VA, Feldstein E, Kane JR, Kang SJ, Lee-Chang C et al. TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clin Cancer Res 2021 Oct 15;27(20):5669-5680. doi:10.1158/1078-0432.CCR-21-0312
  46. Horbinski C, Zumpf KB, McCortney K, Eoannou D Longitudinal observational study of boxing therapy in Parkinson's disease, including adverse impacts of the COVID-19 lockdown. BMC Neurol 2021 Aug 24;21(1):326. pii:326
  47. Horbinski C, Xi G, Wang Y, Hashizume R, Gopalakrishnan M, Phillips JJ, Houghton P, James CD, Kalapurakal JA The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neurooncol Adv 2021;3(1):vdab085. pii:vdab085
  48. McCord M, Lukas RV, Amidei C, Demars N, Gelb A, Buck J, Sachdev S, Feldman A, Tate M, Dixit K et al. Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neurooncol Adv 2021;3(1):vdab045. pii:vdab045
  49. Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol 2021 Aug;22(8):1103-1114. doi:10.1016/S1470-2045(21)00245-X
  50. Horbinski C, Zumpf KB, McCortney K, Eoannou D Longitudinal Study of Boxing Therapy in Parkinson's Disease, Including Adverse Impacts of the COVID-19 Lockdown. Res Sq 2021 Apr 07;.